Cargando…
Barriers to the Access and Use of Rituximab in Patients with Non-Hodgkin’s Lymphoma and Chronic Lymphocytic Leukemia: A Physician Survey
Biologics such as rituximab are an important component of oncology treatment strategies, although access to such therapies is challenging in countries with limited resources. This study examined access to rituximab and identified potential barriers to its use in the United States, Mexico, Turkey, Ru...
Autores principales: | Baer, William H., Maini, Archana, Jacobs, Ira |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2014
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4035768/ https://www.ncbi.nlm.nih.gov/pubmed/24810947 http://dx.doi.org/10.3390/ph7050530 |
Ejemplares similares
-
Efficacy and safety of biosimilar rituximab (ZytuxTM) in newly diagnosed patients with non-Hodgkin lymphoma and chronic lymphocytic leukemia
por: Alwan, Alaa Fadhil, et al.
Publicado: (2020) -
Contemporary Management of Hodgkin Lymphoma and Chronic Lymphocytic Leukemia
por: Kurtin, Sandra E., et al.
Publicado: (2018) -
Rituximab in the treatment of non-Hodgkin’s lymphoma
por: Hauptrock, Beate, et al.
Publicado: (2008) -
Hodgkin lymphoma transformation of chronic lymphocytic leukemia: cases report and discussion
por: Kaźmierczak, Maciej, et al.
Publicado: (2013) -
Subcutaneous Rituximab in Follicular Lymphoma, Chronic Lymphocytic Leukemia, and Diffuse Large B-Cell Lymphoma
por: Yelvington, Bradley J.
Publicado: (2018)